Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML)

Koichi Takahashi, MD, Naveen Pemmaraju, M.D., Miloslav Beran, Alfonso Quintás-Cardama, M.D., Jorge E. Cortes, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, PhD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Elias J. Jabbour, MD, Naval Daver, MD, Zeev Estrov, MD, PhD, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3797.

https://doi.org/10.1182/blood.V120.21.3797.3797

Published: 2012

Journal Articles

Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.

Aziz Nazha, Carlos E. Bueso-Ramos, MD, PhD, Stefan Faderl, MD, Elihu H. Estey, MD, Susan M. O'Brien, Michael Farnandez, Martin Nguyen, Charles Koller, MD, Emil Freireich, MD, Miloslav Beran, Sherry Pierce, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 2616.

https://doi.org/10.1182/blood.V120.21.2616.2616

Published: 2012

Journal Articles

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

Blood (2009) 114 (1): 144–147.

https://doi.org/10.1182/blood-2009-03-210039

Published: 2009

Includes: Supplemental data

Journal Articles

Outcomes in Patients with Chronic Myelomonocytic Leukemia: Analysis of 279 Patients.

Gautam Borthakur, MD, Miloslav Beran, Jun Liu, Dushyant Verma, Xiao Q Dong, Gabriela Rondon, MD, Richard E. Champlin, Hagop Kantarjian, MD, Uday R Popat

Blood (2008) 112 (11): 3235.

https://doi.org/10.1182/blood.V112.11.3235.3235

Published: 2008

Journal Articles

Phase II Study of Thymoglobulin, Cyclosporine and G-CSF for Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome

Ravi n Jain Garg, M.D., Guillermo Garcia-Manero, MD, Stefan Faderl, MD, Jorge Cortes, MD, Charles Asa Koller, Miloslav Beran, Gautam Borthakur, MD, Hagop M Kantarjian, Farhad Ravandi, MBBS

Blood (2008) 112 (11): 5080.

https://doi.org/10.1182/blood.V112.11.5080.5080

Published: 2008

Journal Articles

Results of a Randomized Phase 2 Study of Clofarabine Plus Cytarabine (CA) Vs Clofarabine Plus Idarubicin (CI) Vs Clofarabine, Idarubicin, Plus Cytarabine (CIA) as Salvage Therapy in Acute Myeloid Leukemia (AML).

Stefan Faderl, Gautam Borthakur, Farhad Ravandi, Xuelin Huang, Miloslav Beran, Alessandra Ferrajoli, Charles A. Koller, Deborah A. Thomas, Srdan Verstovsek, Monica Kwari, Hagop M. Kantarjian

Blood (2008) 112 (11): 964.

https://doi.org/10.1182/blood.V112.11.964.964

Published: 2008

Journal Articles

Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center.

Fabio P.S. Santos, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Charles A. Koller, MD, Miloslav Beran, MD, PhD, Gautam Borthakur, MD, Carlos Bueso-Ramos, MD, PhD, Michael Keating, MB, BS, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2008) 112 (11): 925.

https://doi.org/10.1182/blood.V112.11.925.925

Published: 2008

Journal Articles

Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (FTS), a Novel Oral Ras Inhibitor, in Patients with Refractory Hematologic Malignancies.

Gautam Borthakur, MD, Farhad Ravandi, MD, Susan O’Brien, MD, Miloslav Beran, MD, Betsy Williams, RN, Howard Goldsweig, MD, Francis Giles, MD

Blood (2007) 110 (11): 1600.

https://doi.org/10.1182/blood.V110.11.1600.1600

Published: 2007

Journal Articles

Leukemogenic FLT3 Mutations Confer Enhanced Proliferation and Survival Properties to Multipotent Progenitor Cells in a Murine Model of Chronic Myelomonocytic Leukemia.

Benjamin H. Lee, Zuzana Tothova, Ross L. Levine, Kristina Anderson, Natalija Buza-Vidas, Dana E. Cullen, Elizabeth P. McDowell, Jennifer Adelsperger, Stefan Frohling, Brian J.P. Huntly, Miloslav Beran, Sten Eirik Jacobsen, D. Gary Gilliland

Blood (2007) 110 (11): 1613.

https://doi.org/10.1182/blood.V110.11.1613.1613

Published: 2007

Journal Articles

An Interim Analysis of Phase II, Open Randomized Comparative Trial: Alternate or Multiple-Day Dosing of Palonosetron (PALO) Is Effective and Safe in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (pts) with Leukemia Receiving High Dose Ara-C (HDAC).

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Jennifer Cassat, Deborah Blamble, PHDP, B. Nebiyou Bekele, PhD, Miloslav Beran, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Jan Burger, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 2840.

https://doi.org/10.1182/blood.V110.11.2840.2840

Published: 2007

Journal Articles

Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

Stefan Faderl, MD, Deborah A. Thomas, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Miloslav Beran, MD PhD, Michael Rytting, MD, Charles A. Koller, MD, Srdan Verstovsek, MD PhD, Gautam Borthakur, MD, Michael Andreeff, MD PhD, Steve Kornblau, MD, Susan O’Brien, MD, Khanh Vu, MD, Monica Kwari, RN, Jennie Bretz, RN, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 4324.

https://doi.org/10.1182/blood.V110.11.4324.4324

Published: 2007

Journal Articles

Update of the Modified Hyper-CVAD Regimen with or without Rituximab as Frontline Therapy of Adults with Acute Lymphocytic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Charles Koller, MD, Farhad Ravandi-Kashani, MD, Miloslav Beran, MD, PhD, Susan O’Brien, MD

Blood (2007) 110 (11): 2824.

https://doi.org/10.1182/blood.V110.11.2824.2824

Published: 2007

Journal Articles

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

William G. Wierda, Susan O'Brien, Xuemei Wang, Stefan Faderl, Alessandra Ferrajoli, Kim-Anh Do, Jorge Cortes, Deborah Thomas, Guillermo Garcia-Manero, Charles Koller, Miloslav Beran, Francis Giles, Farhad Ravandi, Susan Lerner, Hagop Kantarjian, Michael Keating

Blood (2007) 109 (11): 4679–4685.

https://doi.org/10.1182/blood-2005-12-051458

Published: 2007

Journal Articles

Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study

Steven M. Kornblau, Deborah E. Banker, Derek Stirewalt, Danny Shen, Elizabeth Lemker, Srdan Verstovsek, Zeev Estrov, Stefan Faderl, Jorge Cortes, Miloslav Beran, C. Ellen Jackson, Wenjing Chen, Elihu Estey, Frederick R. Appelbaum

Blood (2006) 109 (7): 2999–3006.

https://doi.org/10.1182/blood-2006-08-044446

Published: 2006

Includes: Supplemental data

Journal Articles

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Jeffrey L. Jorgensen, MD, PhD, Stefan Faderl, MD, Jorge Cortes, MD, Francis Giles, MD, Guillermo Garcia-Manero, MD, William Wierda, MD, PhD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Charles Asa Koller, MD, Miloslav Beran, MD, PhD, Steven M. Kornblau, MD, PhD, Michael Andreeff, MD, PhD, Dan Jones, MD, PhD, Susan O’Brien, MD

Blood (2006) 108 (11): 1861.

https://doi.org/10.1182/blood.V108.11.1861.1861

Published: 2006

Journal Articles

Phase II Study of Thymglobulin, Cyclosporin, and G-CSF for the Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome.

Farhad Ravandi-Kashani, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Miloslav Beran, MD, Sherry Pierce, RN, Charles A. Koller, MD, Jorge Cortes, MD, Stefan Faderl, MD, Hagop M. Kantarjian, MD

Blood (2006) 108 (11): 4830.

https://doi.org/10.1182/blood.V108.11.4830.4830

Published: 2006

Journal Articles

Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage.

Stefan Faderl, MD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, PhD, Gautam Borthakur, MD, Deborah Thomas, MD, Jorge Cortes, MD, Steven M. Kornblau, MD, Zeev Estrov, MD, Michael Andreeff, MD, PhD, Miloslav Beran, MD, PhD, DVM, Francis Giles, MD, Xuelin Huang, PhD, Monica Kwari, RN, Hagop M. Kantarjian, MD

Blood (2006) 108 (11): 159.

https://doi.org/10.1182/blood.V108.11.159.159

Published: 2006

Journal Articles

Granulocytic Sarcoma (GS) Is Associated with Event-Free Survival Superior to That of Acute Myeloid Leukemia (AML).

Apostolia-Maria Tsimberidou, MD, PhD, Michael J. Keating, M.D., Hagop M. Kantarjian, M.D., Susan O’Brien, M.D., Jorge Cortes, M.D., Charles Koller, M.D., BA, Francis Giles, M.D., Sherry Pierce, BSN, BA, Mark Brandt, Miloslav Beran, M.D., Ph.D., Elihu Estey, M.D.

Blood (2006) 108 (11): 2008.

https://doi.org/10.1182/blood.V108.11.2008.2008

Published: 2006

Journal Articles

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Bruce D. Cheson, Peter L. Greenberg, John M. Bennett, Bob Lowenberg, Pierre W. Wijermans, Stephen D. Nimer, Antonio Pinto, Miloslav Beran, Theo M. de Witte, Richard M. Stone, Moshe Mittelman, Guillermo F. Sanz, Steven D. Gore, Charles A. Schiffer, Hagop Kantarjian

Blood (2006) 108 (2): 419–425.

https://doi.org/10.1182/blood-2005-10-4149

Published: 2006

Journal Articles

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

Stefan Faderl, Srdan Verstovsek, Jorge Cortes, Farhad Ravandi, Miloslav Beran, Guillermo Garcia-Manero, Alessandra Ferrajoli, Zeev Estrov, Susan O'Brien, Charles Koller, Francis J. Giles, William Wierda, Monica Kwari, Hagop M. Kantarjian

Blood (2006) 108 (1): 45–51.

https://doi.org/10.1182/blood-2005-08-3294

Published: 2006

NARROW

Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML)

Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

Outcomes in Patients with Chronic Myelomonocytic Leukemia: Analysis of 279 Patients.

Phase II Study of Thymoglobulin, Cyclosporine and G-CSF for Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome

Results of a Randomized Phase 2 Study of Clofarabine Plus Cytarabine (CA) Vs Clofarabine Plus Idarubicin (CI) Vs Clofarabine, Idarubicin, Plus Cytarabine (CIA) as Salvage Therapy in Acute Myeloid Leukemia (AML).

Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center.

Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (FTS), a Novel Oral Ras Inhibitor, in Patients with Refractory Hematologic Malignancies.

Leukemogenic FLT3 Mutations Confer Enhanced Proliferation and Survival Properties to Multipotent Progenitor Cells in a Murine Model of Chronic Myelomonocytic Leukemia.

An Interim Analysis of Phase II, Open Randomized Comparative Trial: Alternate or Multiple-Day Dosing of Palonosetron (PALO) Is Effective and Safe in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (pts) with Leukemia Receiving High Dose Ara-C (HDAC).

Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

Update of the Modified Hyper-CVAD Regimen with or without Rituximab as Frontline Therapy of Adults with Acute Lymphocytic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

Phase II Study of Thymglobulin, Cyclosporin, and G-CSF for the Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome.

Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage.

Granulocytic Sarcoma (GS) Is Associated with Event-Free Survival Superior to That of Acute Myeloid Leukemia (AML).

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only